HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)
Research To Practice | Oncology Videos · Dr. Neil Love
October 13, 202531m 9s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:
- Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
- Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
- Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)